Efficacy and safety of a combination of metformin and rosiglitazone in patients with type 2 diabetes mellitus - A postmarketing study

Journal of the Indian Medical Association

Volumn 101, Issue 2, 2003, Pages

  Ballary, Chetna ^a   Desai, Anish ^a  

^a Glenmark Pharmaceuticals Limited   (India)

Author keywords

Insulin resistance; Insulin sentisiser; Metformin and rosiglitazone combination; Oral hypoglycaemic agents; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; LIVER ENZYME; METFORMIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; GOOD CLINICAL PRACTICE; HEADACHE; HUMAN; INDIA; INSULIN RESISTANCE; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; REVIEW; VERTIGO; ANALYSIS OF VARIANCE; ARTICLE; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0041706629     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. King H, Aubert RE, Herman WH - Global burden of diabetes. 1995-2025. Diabetes Care 1998; 21: 1414-31.
2. Powers AC - Diabetes mellitus. In: Braunwald E, Fauci AS, Kisper DL, et al, editors. Harrison's Principles of Internal Medicine. Vol 2. 15th ed. New York: McGraw Hill, 2001: 2109-37.
3. Turner RC, Culi CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group - Glycemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus. JAMA 1999; 281: 2005-12.
4. Goldstein BJ - Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2001; 90: 3G.
5. Wagsmff AJ, Goa KL - Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
6. Davis SN, Granner DK - Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG and Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw Hill, 2001: 1679-1714.
7. De Fronzo RA - Pharmacologic therapy for type 2 diabetes mellitu. Ann Intern Med 1999; 131: 281-303.
8. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet t998: 352: 854-65.
9. valle F, Bell DS - Differing effects of thiazolidinediones on LDL and HDL subfraction and Lp(a). Diabetes 2001; 50: A453-4, A461-2.
10. Bell DS, Mayo MS - Weight loss in patients treated with a metformin sulphonylurea combination in comparison with twice daily mixed insulin. Endocr Prac 1998; 4: 360-4.
11. Fonseca V, Rosenstock J, Patwardhan R, Salzman A - Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000; 283: 1695-702.
12. Chu NV, Kim DD, Kong AP, et al - Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes mellitus. Diabetes 2000; 49: A101.